Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Converting from Transdermal to Buccal Formulations of Buprenorphine: A Pharmacokinetic Meta-Model Simulation in Healthy Volunteers.

Priestley T, Chappa AK, Mould DR, Upton RN, Shusterman N, Passik S, Tormo VJ, Camper S.

Pain Med. 2018 Oct 1;19(10):1988-1996. doi: 10.1093/pm/pnx235.

PMID:
29036723
2.

Results of the first interim analysis of the RAPPER II trial in patients with spinal cord injury: ambulation and functional exercise programs in the REX powered walking aid.

Birch N, Graham J, Priestley T, Heywood C, Sakel M, Gall A, Nunn A, Signal N.

J Neuroeng Rehabil. 2017 Jun 19;14(1):60. doi: 10.1186/s12984-017-0274-6.

3.

EN3427: a novel cationic aminoindane with long-acting local anesthetic properties.

Banerjee M, Baranwal A, Saha S, Saha A, Priestley T.

Anesth Analg. 2015 Apr;120(4):941-9. doi: 10.1213/ANE.0000000000000629.

PMID:
25695675
4.

Using wastewater and high-rate algal ponds for nutrient removal and the production of bioenergy and biofuels.

Batten D, Beer T, Freischmidt G, Grant T, Liffman K, Paterson D, Priestley T, Rye L, Threlfall G.

Water Sci Technol. 2013;67(4):915-24. doi: 10.2166/wst.2012.618.

PMID:
23306273
5.

T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesis.

Smith EM, Sorota S, Kim HM, McKittrick BA, Nechuta TL, Bennett C, Knutson C, Burnett DA, Kieselgof J, Tan Z, Rindgen D, Bridal T, Zhou X, Jia YP, Dong Z, Mullins D, Zhang X, Priestley T, Correll CC, Tulshian D, Czarniecki M, Greenlee WJ.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4602-6. doi: 10.1016/j.bmcl.2010.06.012. Epub 2010 Jun 8.

PMID:
20580233
6.

Protein binding-dependent decreases in hERG channel blocker potency assessed by whole-cell voltage clamp in serum.

Margulis M, Sorota S, Chu I, Soares A, Priestley T, Nomeir AA.

J Cardiovasc Pharmacol. 2010 Apr;55(4):368-76. doi: 10.1097/FJC.0b013e3181d2ce39.

PMID:
20125032
7.

Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.

Scott JD, Miller MW, Li SW, Lin SI, Vaccaro HA, Hong L, Mullins DE, Guzzi M, Weinstein J, Hodgson RA, Varty GB, Stamford AW, Chan TY, McKittrick BA, Greenlee WJ, Priestley T, Parker EM.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. doi: 10.1016/j.bmcl.2009.09.050. Epub 2009 Sep 17.

PMID:
19800231
8.

Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.

Aslanian R, Piwinski JJ, Zhu X, Priestley T, Sorota S, Du XY, Zhang XS, McLeod RL, West RE, Williams SM, Hey JA.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7. doi: 10.1016/j.bmcl.2009.07.047. Epub 2009 Aug 5.

PMID:
19660947
9.

Predicting therapeutic efficacy - experimental pain in human subjects.

Chizh BA, Priestley T, Rowbotham M, Schaffler K.

Brain Res Rev. 2009 Apr;60(1):243-54. doi: 10.1016/j.brainresrev.2008.12.016. Epub 2008 Dec 31. Review.

PMID:
19168094
10.

The antipsychotic drug, fluphenazine, effectively reverses mechanical allodynia in rat models of neuropathic pain.

Dong XW, Jia Y, Lu SX, Zhou X, Cohen-Williams M, Hodgson R, Li H, Priestley T.

Psychopharmacology (Berl). 2008 Jan;195(4):559-68. Epub 2007 Sep 23.

PMID:
17891479
11.

Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis.

Yang SW, Chan TM, Buevich A, Priestley T, Crona J, Reed J, Wright AE, Patel M, Gullo V, Chen G, Pramanik B, Chu M.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5543-7. Epub 2007 Aug 16.

PMID:
17804230
12.

Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats.

Dong XW, Goregoaker S, Engler H, Zhou X, Mark L, Crona J, Terry R, Hunter J, Priestley T.

Neuroscience. 2007 May 11;146(2):812-21. Epub 2007 Mar 23.

PMID:
17367951
13.

The neuroleptic drug, fluphenazine, blocks neuronal voltage-gated sodium channels.

Zhou X, Dong XW, Priestley T.

Brain Res. 2006 Aug 23;1106(1):72-81. doi: 10.1016/j.brainres.2006.05.076. Epub 2006 Jul 12.

PMID:
16839522
14.

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.

Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Priestley T, Sorota S, Huang W, Hirsch M, Reyes GR, Baroudy BM.

Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9.

15.

Regulation of two rat mas-related genes in a model of neuropathic pain.

Gustafson EL, Maguire M, Campanella M, Tarozzo G, Jia Y, Dong XW, Laverty M, Murgolo N, Priestley T, Reggiani A, Monsma F, Beltramo M.

Brain Res Mol Brain Res. 2005 Dec 7;142(1):58-64. Epub 2005 Oct 24.

PMID:
16246453
16.

Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.

Sorota S, Zhang XS, Margulis M, Tucker K, Priestley T.

Assay Drug Dev Technol. 2005 Feb;3(1):47-57.

PMID:
15798395
17.

Voltage-gated sodium channels and pain.

Priestley T.

Curr Drug Targets CNS Neurol Disord. 2004 Dec;3(6):441-56. Review.

PMID:
15578963
18.

Electrophysiological analysis of tetrodotoxin-resistant sodium channel pharmacology.

Dong XW, Priestley T.

Curr Protoc Pharmacol. 2004 Feb;Chapter 11:Unit11.8. doi: 10.1002/0471141755.ph1108s23.

PMID:
21956811
19.

Vinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-resistant sodium channels.

Zhou X, Dong XW, Crona J, Maguire M, Priestley T.

J Pharmacol Exp Ther. 2003 Aug;306(2):498-504. Epub 2003 May 1.

PMID:
12730276
20.

Long-term potentiation is increased in the CA1 area of the hippocampus of APP(swe/ind) CRND8 mice.

Jolas T, Zhang XS, Zhang Q, Wong G, Del Vecchio R, Gold L, Priestley T.

Neurobiol Dis. 2002 Dec;11(3):394-409.

PMID:
12586549
22.

The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption.

Altmann SW, Davis HR Jr, Yao X, Laverty M, Compton DS, Zhu LJ, Crona JH, Caplen MA, Hoos LM, Tetzloff G, Priestley T, Burnett DA, Strader CD, Graziano MP.

Biochim Biophys Acta. 2002 Jan 30;1580(1):77-93.

PMID:
11923102
23.

Nociceptin/orphanin FQ inhibits capsaicin-induced guinea-pig airway contraction through an inward-rectifier potassium channel.

Jia Y, Wang X, Aponte SI, Rivelli MA, Yang R, Rizzo CA, Corboz MR, Priestley T, Hey JA.

Br J Pharmacol. 2002 Feb;135(3):764-70.

25.

In vitro propagation and inducible differentiation of multipotential progenitor cells from human fetal brain.

Chalmers-Redman RM, Priestley T, Kemp JA, Fine A.

Neuroscience. 1997 Feb;76(4):1121-8.

PMID:
9027872
26.

Time-dependent changes in NMDA receptor expression in neurones cultured from rat brain.

Priestley T, Ochu E, Macaulay AJ.

Brain Res Mol Brain Res. 1996 Sep 1;40(2):271-4.

PMID:
8872311
27.

The effects of insulin-like growth factor analogues on survival of cultured cerebral cortex and cerebellar granule neurones.

Harper SJ, Macaulay AJ, Hill RG, Priestley T.

Brain Res. 1996 Feb 19;709(2):303-10.

PMID:
8833767
28.

Electrophysiological characterisation of the antagonist properties of two novel NMDA receptor glycine site antagonists, L-695,902 and L-701,324.

Priestley T, Laughton P, Macaulay AJ, Hill RG, Kemp JA.

Neuropharmacology. 1996;35(11):1573-81.

PMID:
9025105
29.
31.

Subtypes of NMDA receptor in neurones cultured from rat brain.

Priestley T, Ochu E, Kemp JA.

Neuroreport. 1994 Sep 8;5(14):1763-5.

PMID:
7827326
33.

Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-D-aspartate receptor from rat brain.

Foster AC, Kemp JA, Leeson PD, Grimwood S, Donald AE, Marshall GR, Priestley T, Smith JD, Carling RW.

Mol Pharmacol. 1992 May;41(5):914-22.

PMID:
1375317
34.
35.
37.

The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures.

Priestley T, Horne AL, McKernan RM, Kemp JA.

Brain Res. 1990 Oct 29;531(1-2):183-8.

PMID:
2149665
38.

The glycine site on the NMDA receptor: pharmacology and involvement in NMDA receptor-mediated neurodegeneration.

Foster AC, Donald AE, Willis CL, Tridgett R, Kemp JA, Priestley T.

Adv Exp Med Biol. 1990;268:93-100. Review. No abstract available.

PMID:
2150161
39.
41.

7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex.

Kemp JA, Foster AC, Leeson PD, Priestley T, Tridgett R, Iversen LL, Woodruff GN.

Proc Natl Acad Sci U S A. 1988 Sep;85(17):6547-50.

42.
43.
44.

The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.

Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL.

Proc Natl Acad Sci U S A. 1986 Sep;83(18):7104-8.

45.

Pharmacological distinction between two muscarinic responses on the isolated superior cervical ganglion of the rat.

Newberry NR, Priestley T, Woodruff GN.

Eur J Pharmacol. 1985 Oct 8;116(1-2):191-2. No abstract available.

PMID:
3840438
46.

In vivo evidence for the selectivity of ICI 154129 for the delta-opioid receptor.

Priestley T, Turnbull MJ, Wei E.

Neuropharmacology. 1985 Feb;24(2):107-10.

PMID:
2986029
47.

In vivo evaluation of the opiate delta receptor antagonist ICI 154, 129.

Gormley JJ, Morley JS, Priestley T, Shaw JS, Turnbull MJ, Wheeler H.

Life Sci. 1982 Sep 20-27;31(12-13):1263-6. No abstract available.

PMID:
6292612

Supplemental Content

Loading ...
Support Center